Targeting neo-antigens to potentiate specific anti-tumor immune responses is not JUST going to help improve the clinical response rate (20-80%) of immune checkpoint inhibitors. It means that those fighting cancer have another real chance at long-term remission--an opportunity to see their children and grandchildren grow up. The successful progression of this combination therapy to phase 3 hits home to anyone who has lost or currently has a loved one fighting cancer, bravo! #cancersucks #immunology
Moderna and Merck announced today the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating mRNA-4257 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) #melanoma. Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia. Read more: https://lnkd.in/eZTgaFJW